Dongliang Guan
Dongliang Guan has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
Fang Li
Bohai Rim Advanced Research Institute for Drug Discovery
12 shared publicationsJinyong Zhang
Army Medical University
10 shared publicationsZhifu Chen
Army Medical University
10 shared publications- Wei Huang
Key Laboratory of Glyco-drug Research of Zhejiang Province, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China
7 shared publications Taopeng Chang
Shandong Laboratory of Yantai Drug Discovery
6 shared publications- Feifei Chen
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by American Chemical Society (ACS) in JACS Au
Reprogramming the Kyn-13 Locus of Daptomycin Unlocks a Serendipitous Theranostic Paradigm
Driven by the escalating multidrug-resistant superbug crisis (e.g., methicillin- and vancomycin-resistant strains) and the sparse clinical lipopeptide pipeline, we designed and synthesized 36 daptomycin derivatives, termed “kynurarylmycins”, based on the facile regiospecific reductive amination approach at the Kyn-13 site of daptomycin with diverse aromatic aldehydes. Systematic SAR analysis revealed Kyn-13 arylation as a highly effective strategy to boost antibacterial potency. The lead candidate Dap-34 exhibits outstanding broad-spectrum activity against high-priority Gram-positive pathogens, including clinical isolates, outperforming daptomycin and vancomycin by 32- and 512-fold, respectively. Mechanistically, Dap-34 disrupts cell envelope activity via two independent pathways: it induces faster and stronger membrane depolarization with mild permeabilization to disrupt membrane homeostasis, and augments inhibition of cell wall biosynthesis. This dual-targeted lethality translates into superior in vivo therapeutic efficacy in murine infection models. Serendipitously, this modification remodels daptomycin′s intrinsic photophysics, triggering marked fluorescence turn-on in bacterial lipid microenvironments for high-contrast, wash-free, label-free live imaging. This work redefines Kyn-13 as a dual pharmacological and photophysical hub, offering an unprecedented theranostic paradigm for combating antimicrobial resistance.
- 29 October 2026
- Published by American Chemical Society (ACS) in JACS Au
Open AccessReprogramming the Kyn-13 Locus of Daptomycin Unlocks a Serendipitous Theranostic Paradigm
Driven by the escalating multidrug-resistant superbug crisis (e.g., methicillin- and vancomycin-resistant strains) and the sparse clinical lipopeptide pipeline, we designed and synthesized 36 daptomycin derivatives, termed “kynurarylmycins”, based on the facile regiospecific reductive amination approach at the Kyn-13 site of daptomycin with diverse aromatic aldehydes. Systematic SAR analysis revealed Kyn-13 arylation as a highly effective strategy to boost antibacterial potency. The lead candidate Dap-34 exhibits outstanding broad-spectrum activity against high-priority Gram-positive pathogens, including clinical isolates, outperforming daptomycin and vancomycin by 32- and 512-fold, respectively. Mechanistically, Dap-34 disrupts cell envelope activity via two independent pathways: it induces faster and stronger membrane depolarization with mild permeabilization to disrupt membrane homeostasis, and augments inhibition of cell wall biosynthesis. This dual-targeted lethality translates into superior in vivo therapeutic efficacy in murine infection models. Serendipitously, this modification remodels daptomycin′s intrinsic photophysics, triggering marked fluorescence turn-on in bacterial lipid microenvironments for high-contrast, wash-free, label-free live imaging. This work redefines Kyn-13 as a dual pharmacological and photophysical hub, offering an unprecedented theranostic paradigm for combating antimicrobial resistance.
- 7 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23601-23621
Sulfonium Modification of Echinocandins: An Effective Strategy to Combat Intrinsically Resistant Cryptococcus via Membrane Disruption and Enhanced Cell Wall Biosynthesis Inhibition
Fungal infections claim millions of lives annually and intrinsic resistance of Cryptococcus against echinocandins severely impedes clinical treatment. In this study, sulfonium covalent modification was performed based on natural pneumocandin B0 scaffold. The obtained derivatives exhibited potent activity against Candida species and reversed innate resistance of Cryptococcus neoformans, with MIC values reaching as low as 2 μg/mL. Structural modification elevated fungal membrane permeability and induced membrane depolarization, while enhancing the inhibitory effect on glucan synthase and disturbing cell wall biosynthesis. Compounds 3h and 5h possessed low drug resistance potential, favorable safety profiles, satisfactory pharmacokinetic properties and robust in vivo antifungal efficacy. This modification strategy facilitates the development of novel antifungal candidates.
- 7 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23601-23621
Sulfonium Modification of Echinocandins: An Effective Strategy to Combat Intrinsically Resistant Cryptococcus via Membrane Disruption and Enhanced Cell Wall Biosynthesis Inhibition
Fungal infections claim millions of lives annually and intrinsic resistance of Cryptococcus against echinocandins severely impedes clinical treatment. In this study, sulfonium covalent modification was performed based on natural pneumocandin B0 scaffold. The obtained derivatives exhibited potent activity against Candida species and reversed innate resistance of Cryptococcus neoformans, with MIC values reaching as low as 2 μg/mL. Structural modification elevated fungal membrane permeability and induced membrane depolarization, while enhancing the inhibitory effect on glucan synthase and disturbing cell wall biosynthesis. Compounds 3h and 5h possessed low drug resistance potential, favorable safety profiles, satisfactory pharmacokinetic properties and robust in vivo antifungal efficacy. This modification strategy facilitates the development of novel antifungal candidates.
- 15 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20782-20803
Rational N-Terminal Tuning of Bacitracin A: Repurposing a Classic Antibiotic to Combat Multidrug-Resistant Gram-Positive Pathogens
The increasing threat of infections caused by multidrug-resistant Gram-positive pathogens such as MRSA and VRE has driven the structural remodeling and repurposing of traditional antibiotics as a key strategy to combat bacterial resistance. Herein, using bacitracin A as a lead template, we established a site-selective semisynthetic modification strategy via reductive amination of its N-terminal primary amine. 32 derivatives were designed and synthesized, and their structure–activity relationships were systematically evaluated. Optimized derivatives exhibited potent activity against MRSA and VRE, with 4–32-fold enhanced antibacterial potency compared with bacitracin A, together with improved bactericidal properties, safety profiles, and pharmacokinetic characteristics. Mechanistically, hydrophobic N-terminal modification endows bacitracin A with multiple antibacterial modes, including enhanced inhibition of cell wall peptidoglycan biosynthesis, obvious membrane depolarization, and disruption of the purine metabolic pathway. These findings provide a rational strategy for bacitracin optimization and highlight the potential of N-terminal modification for developing improved antibacterial agents.
- 15 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20782-20803
Rational N-Terminal Tuning of Bacitracin A: Repurposing a Classic Antibiotic to Combat Multidrug-Resistant Gram-Positive Pathogens
The increasing threat of infections caused by multidrug-resistant Gram-positive pathogens such as MRSA and VRE has driven the structural remodeling and repurposing of traditional antibiotics as a key strategy to combat bacterial resistance. Herein, using bacitracin A as a lead template, we established a site-selective semisynthetic modification strategy via reductive amination of its N-terminal primary amine. 32 derivatives were designed and synthesized, and their structure–activity relationships were systematically evaluated. Optimized derivatives exhibited potent activity against MRSA and VRE, with 4–32-fold enhanced antibacterial potency compared with bacitracin A, together with improved bactericidal properties, safety profiles, and pharmacokinetic characteristics. Mechanistically, hydrophobic N-terminal modification endows bacitracin A with multiple antibacterial modes, including enhanced inhibition of cell wall peptidoglycan biosynthesis, obvious membrane depolarization, and disruption of the purine metabolic pathway. These findings provide a rational strategy for bacitracin optimization and highlight the potential of N-terminal modification for developing improved antibacterial agents.
- 15 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10993-11023
Discovery of New Teraryl γ-Lactam Derivatives as Potent Antibacterial Agents In Vitro and In Vivo through Dual Cell Wall–Membrane Inhibitions
Antimicrobial resistance threatens global public health, urgently requiring new antibiotics. Herein, we report a novel antibacterial scaffold with a 1,2,4-oxadiazole teraryl moiety and γ-lactam fragment via bacteria-based phenotypic screening. Diversified modifications of its four sites yielded 42 derivatives, and comprehensive SAR analysis against multidrug-resistant "superbugs" identified lead compound 8c. 8c exhibits excellent activity against drug-resistant Gram-positive bacteria (e.g., MRSA, VISA, VRE), 4-32-fold more potent than ciprofloxacin and meropenem. 8c shows rapid bactericidal activity, a low propensity to induce resistance, and a moderate safety profile. Mechanistically, 8c inhibits peptidoglycan biosynthesis by targeting the Lipid II cycle and disrupts membrane homeostasis via enhanced permeability and induced hyperpolarization, with this dual action validated by proteomic and lipidomic analyses. It also has excellent liver microsomal stability, favorable in vivo pharmacokinetics, and potent in vivo anti-MRSA efficacy. This novel scaffold is a promising addition to the antibiotic arsenal and warrants further development.
- 15 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10993-11023
Discovery of New Teraryl γ-Lactam Derivatives as Potent Antibacterial Agents In Vitro and In Vivo through Dual Cell Wall–Membrane Inhibitions
Antimicrobial resistance threatens global public health, urgently requiring new antibiotics. Herein, we report a novel antibacterial scaffold with a 1,2,4-oxadiazole teraryl moiety and γ-lactam fragment via bacteria-based phenotypic screening. Diversified modifications of its four sites yielded 42 derivatives, and comprehensive SAR analysis against multidrug-resistant "superbugs" identified lead compound 8c. 8c exhibits excellent activity against drug-resistant Gram-positive bacteria (e.g., MRSA, VISA, VRE), 4-32-fold more potent than ciprofloxacin and meropenem. 8c shows rapid bactericidal activity, a low propensity to induce resistance, and a moderate safety profile. Mechanistically, 8c inhibits peptidoglycan biosynthesis by targeting the Lipid II cycle and disrupts membrane homeostasis via enhanced permeability and induced hyperpolarization, with this dual action validated by proteomic and lipidomic analyses. It also has excellent liver microsomal stability, favorable in vivo pharmacokinetics, and potent in vivo anti-MRSA efficacy. This novel scaffold is a promising addition to the antibiotic arsenal and warrants further development.
- 12 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (21) , e2167334
Amphiphilic Zwitterionic Polymers Induce Liposome Morphogenesis into Nanodiscs for Deep Glioblastoma Infiltration
Glioblastoma therapy is severely constrained by the blood–brain barrier (BBB) and limited intratumoral penetration. Here, we report a de novo synthesized amphiphilic zwitterionic copolymer that co‐assembles with phospholipids into protein‐free nanodiscs (zNDs, ∼15.5 nm). Liposome co‐flotation and Förster resonance energy transfer (FRET) assays reveal a three‐stage morphogenetic process: polymer insertion, membrane disruption, and liposome‐to‐nanodisc reassembly through membrane remodeling. The resulting zNDs exhibit high colloidal stability under physiological conditions and efficiently cross the BBB via choline transporter‐mediated transcytosis. In orthotopic glioblastoma models, zNDs penetrate tumors deeply, enter cells through clathrin‐mediated endocytosis, and escape endo‐lysosomal compartments. Incorporation of lipid–drug conjugates allows delivery of honokiol, which disassembles 3D tumor spheroids, suppresses tumor growth in orthotopic models, and extends median survival by nearly 2.5‐fold without systemic toxicity. This study establishes a modular, protein‐free nanodisc platform that integrates rational polymer design with active BBB transport, offering a versatile strategy for deep therapeutic delivery in central nervous system malignancies and providing mechanistic principles that guide future optimization of BBB‐penetrant nanocarriers.
- 12 April 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (21) , e2167334
Amphiphilic Zwitterionic Polymers Induce Liposome Morphogenesis into Nanodiscs for Deep Glioblastoma Infiltration
Glioblastoma therapy is severely constrained by the blood–brain barrier (BBB) and limited intratumoral penetration. Here, we report a de novo synthesized amphiphilic zwitterionic copolymer that co‐assembles with phospholipids into protein‐free nanodiscs (zNDs, ∼15.5 nm). Liposome co‐flotation and Förster resonance energy transfer (FRET) assays reveal a three‐stage morphogenetic process: polymer insertion, membrane disruption, and liposome‐to‐nanodisc reassembly through membrane remodeling. The resulting zNDs exhibit high colloidal stability under physiological conditions and efficiently cross the BBB via choline transporter‐mediated transcytosis. In orthotopic glioblastoma models, zNDs penetrate tumors deeply, enter cells through clathrin‐mediated endocytosis, and escape endo‐lysosomal compartments. Incorporation of lipid–drug conjugates allows delivery of honokiol, which disassembles 3D tumor spheroids, suppresses tumor growth in orthotopic models, and extends median survival by nearly 2.5‐fold without systemic toxicity. This study establishes a modular, protein‐free nanodisc platform that integrates rational polymer design with active BBB transport, offering a versatile strategy for deep therapeutic delivery in central nervous system malignancies and providing mechanistic principles that guide future optimization of BBB‐penetrant nanocarriers.
- 11 April 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (21) , e2167334
Amphiphilic Zwitterionic Polymers Induce Liposome Morphogenesis into Nanodiscs for Deep Glioblastoma Infiltration
Glioblastoma therapy is severely constrained by the blood–brain barrier (BBB) and limited intratumoral penetration. Here, we report a de novo synthesized amphiphilic zwitterionic copolymer that co‐assembles with phospholipids into protein‐free nanodiscs (zNDs, ∼15.5 nm). Liposome co‐flotation and Förster resonance energy transfer (FRET) assays reveal a three‐stage morphogenetic process: polymer insertion, membrane disruption, and liposome‐to‐nanodisc reassembly through membrane remodeling. The resulting zNDs exhibit high colloidal stability under physiological conditions and efficiently cross the BBB via choline transporter‐mediated transcytosis. In orthotopic glioblastoma models, zNDs penetrate tumors deeply, enter cells through clathrin‐mediated endocytosis, and escape endo‐lysosomal compartments. Incorporation of lipid–drug conjugates allows delivery of honokiol, which disassembles 3D tumor spheroids, suppresses tumor growth in orthotopic models, and extends median survival by nearly 2.5‐fold without systemic toxicity. This study establishes a modular, protein‐free nanodisc platform that integrates rational polymer design with active BBB transport, offering a versatile strategy for deep therapeutic delivery in central nervous system malignancies and providing mechanistic principles that guide future optimization of BBB‐penetrant nanocarriers.
- 11 April 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (21) , e2167334
Amphiphilic Zwitterionic Polymers Induce Liposome Morphogenesis into Nanodiscs for Deep Glioblastoma Infiltration
Glioblastoma therapy is severely constrained by the blood–brain barrier (BBB) and limited intratumoral penetration. Here, we report a de novo synthesized amphiphilic zwitterionic copolymer that co‐assembles with phospholipids into protein‐free nanodiscs (zNDs, ∼15.5 nm). Liposome co‐flotation and Förster resonance energy transfer (FRET) assays reveal a three‐stage morphogenetic process: polymer insertion, membrane disruption, and liposome‐to‐nanodisc reassembly through membrane remodeling. The resulting zNDs exhibit high colloidal stability under physiological conditions and efficiently cross the BBB via choline transporter‐mediated transcytosis. In orthotopic glioblastoma models, zNDs penetrate tumors deeply, enter cells through clathrin‐mediated endocytosis, and escape endo‐lysosomal compartments. Incorporation of lipid–drug conjugates allows delivery of honokiol, which disassembles 3D tumor spheroids, suppresses tumor growth in orthotopic models, and extends median survival by nearly 2.5‐fold without systemic toxicity. This study establishes a modular, protein‐free nanodisc platform that integrates rational polymer design with active BBB transport, offering a versatile strategy for deep therapeutic delivery in central nervous system malignancies and providing mechanistic principles that guide future optimization of BBB‐penetrant nanocarriers.
- 27 March 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (6)
Cover Feature: Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE (ChemMedChem 6/2026)
- 27 March 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (6)
Cover Feature: Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE (ChemMedChem 6/2026)
- 26 March 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (6) , e202501084
Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE
Antimicrobial resistance (AMR) poses a significant global public health challenge. Vancomycin and β‐lactam antibiotics, critical for treating multidrug‐resistant (MDR) bacterial infections, are hindered by resistant strains such as vancomycin‐resistant Enterococci (VRE) and vancomycin‐intermediate Staphylococcus aureus , as well as β‐lactamase‐mediated resistance. This article leverages the complementary mechanisms of these antibiotics, which target bacterial cell wall synthesis, to develop vancomycin‐β‐lactam hybrids as a novel strategy against AMR. Through chemical modification, β‐lactam fragments were introduced at the carboxyl (C), resorcinol (R), and amine (N) termini of vancomycin, yielding multiple hybrid series. In vitro activity assays revealed that C‐terminal modified vancomycin–penicillin hybrids exhibited superior efficacy, with compound 6a–6g reducing the minimum inhibitory concentration against strains such as VREs by 512–1024‐fold compared to vancomycin, achieving activity comparable to oritavancin in certain strains. In vitro safety evaluations demonstrated low cytotoxicity of 6a against human kidney (HK2) and embryonic kidney (HEK293) cell lines. These findings establish 6a as a promising drug candidate, offering a novel therapeutic option for MDR infections.
- 26 March 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (6) , e202501084
Novel Vancomycin‐β‐Lactam Hybrids: Structure–Activity Relationships and Therapeutic Potential Against VISA and VRE
Antimicrobial resistance (AMR) poses a significant global public health challenge. Vancomycin and β‐lactam antibiotics, critical for treating multidrug‐resistant (MDR) bacterial infections, are hindered by resistant strains such as vancomycin‐resistant Enterococci (VRE) and vancomycin‐intermediate Staphylococcus aureus , as well as β‐lactamase‐mediated resistance. This article leverages the complementary mechanisms of these antibiotics, which target bacterial cell wall synthesis, to develop vancomycin‐β‐lactam hybrids as a novel strategy against AMR. Through chemical modification, β‐lactam fragments were introduced at the carboxyl (C), resorcinol (R), and amine (N) termini of vancomycin, yielding multiple hybrid series. In vitro activity assays revealed that C‐terminal modified vancomycin–penicillin hybrids exhibited superior efficacy, with compound 6a–6g reducing the minimum inhibitory concentration against strains such as VREs by 512–1024‐fold compared to vancomycin, achieving activity comparable to oritavancin in certain strains. In vitro safety evaluations demonstrated low cytotoxicity of 6a against human kidney (HK2) and embryonic kidney (HEK293) cell lines. These findings establish 6a as a promising drug candidate, offering a novel therapeutic option for MDR infections.
- 9 January 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
Dihydro-α-Pyrone Antibiotics from a Soil-Derived Fungus Talaromyces sp. G23
Nine novel dihydro-α-pyrone derivatives, talaromypyrones A-I (1-9), were isolated from the soil-derived fungus Talaromyces sp. G23. These compounds share a conserved 3'R-configuration within the 4-hydroxy-5,6-dihydro-2-pyrone core but display notable variations in their flanking polyketide chains. Talaromypyrones A-H (1-8) demonstrate potent antibacterial activity against Gram-positive bacteria, including drug-resistant strains, while exhibiting excellent safety profile by showing no cytotoxicity toward normal human LO2 cells. However, they exhibit no activity against Gram-negative bacteria (likely due to their inability to penetrate the outer membrane) and fungi. Such antimicrobial profile, combined with the structural similarity to the α-pyrone antibiotic myxopyronin, suggests a potential target in the switch region of bacterial RNA polymerase (RNAP). Molecular docking studies revealed that talaromypyrone E (5) binds to the same site of RNAP as myxopyronin and forms additional hydrogen bonds between the 4-hydroxy-5,6-dihydro-2-pyrone core and the RNAP residues. Furthermore, talaromypyrones A (1) and D (4) demonstrate moderate anti-inflammatory activity, positioning 4-hydroxy-5,6-dihydro-2-pyrone core as a promising building block for the development of dual-function agents capable of concurrently addressing both conventional and drug-resistant bacterial infections while alleviating associated inflammatory responses.
- 9 January 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
Dihydro-α-Pyrone Antibiotics from a Soil-Derived Fungus Talaromyces sp. G23
Nine novel dihydro-α-pyrone derivatives, talaromypyrones A-I (1-9), were isolated from the soil-derived fungus Talaromyces sp. G23. These compounds share a conserved 3'R-configuration within the 4-hydroxy-5,6-dihydro-2-pyrone core but display notable variations in their flanking polyketide chains. Talaromypyrones A-H (1-8) demonstrate potent antibacterial activity against Gram-positive bacteria, including drug-resistant strains, while exhibiting excellent safety profile by showing no cytotoxicity toward normal human LO2 cells. However, they exhibit no activity against Gram-negative bacteria (likely due to their inability to penetrate the outer membrane) and fungi. Such antimicrobial profile, combined with the structural similarity to the α-pyrone antibiotic myxopyronin, suggests a potential target in the switch region of bacterial RNA polymerase (RNAP). Molecular docking studies revealed that talaromypyrone E (5) binds to the same site of RNAP as myxopyronin and forms additional hydrogen bonds between the 4-hydroxy-5,6-dihydro-2-pyrone core and the RNAP residues. Furthermore, talaromypyrones A (1) and D (4) demonstrate moderate anti-inflammatory activity, positioning 4-hydroxy-5,6-dihydro-2-pyrone core as a promising building block for the development of dual-function agents capable of concurrently addressing both conventional and drug-resistant bacterial infections while alleviating associated inflammatory responses.